Keyword Search
 
2017 | 2016 | 2015
  • Altimmune Announces Acceptance of Heptcell Abstract for Presentation at Bsi/Nvvi Congress 2016
  • December 06, 2016 - ... 
  • Altimmune to Present at THR 28th Annual Piper Jaffray Healthcare Conference
  • November 18, 2016 - ... 
  • Altimmune Announces Poster Presentation of Heptcell Program at 2017 Keystone Symposia Conference
  • October 26, 2016 - ... 
  • Altimmune Announces Addition of Christine Brennan to Board Of Directors
  • September 13, 2016 - ... 
  • Altimmune to Present at 18th Annual Rodman & Renshaw Global Investment Conference
  • August 30, 2016 - ... 
  • Altimmune Receives Barda Contract of Up to $120.2 Million to Fund Clinical Development of First-In-Class Anthrax Vaccine Candidate Nasoshield
  • August 01, 2016 - ... 
  • Altimmune to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
  • July 12, 2016 - ... 
  • Altimmune to Participate in Two Upcoming Conferences
  • May 03, 2016 - ... 
  • Altimmune Announces Participation in Vaccine Development Panel at The Annual Regional Biotech Forum
  • April 13, 2016 - ... 
  • Altimmune Expands Clinical Development Team
  • April 05, 2016 - ... 
  • Altimmune to Present at two Upcoming Conferences
  • March 01, 2016 - ... 
  • Altimmune Announces Presentation at BIO CEO & Investor Conference
  • January 26, 2016 - Gaithersburg, Maryland – Jan. 26, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the BIO CEO & Investor Conference to be held February 8 - 9, 2016 in New York, NY.Bill Enright, Chief Executive Officer of Altimmune, is scheduled to present on Monday, February 8, 2016 at 8:00 a.m. ET.About Altimmune Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and du... 

    © 2017 Altimmune, Inc.   All rights reserved.   Terms of Use